Novo Nordisk recruits 500 people for Alzheimer's trial

Alzheimer’s has been called the graveyard of the pharmaceutical industry, and many companies have failed within the indication. Still, signs indicate that Novo Nordisk has a chance of success with its GLP-1 approach, and Lundbeck’s head of R&D says there’s ”relatively strong reasoning behind it.”

Photo: Tidsvilde Stine/Ritzau Scanpix

The world’s biggest pharmaceutical firms have been trying for decades. Danish Lundbeck is having a go, and recently, Novo Nordisk threw its hat in the ring.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs